Novo Nordisk, manufacturer of the weight loss drug Wegovy, said Thursday that it will continue to restrict supplies of starter doses of the drug in the United States. This restriction will likely continue into next year.
The Danish company has been struggling to meet demand in the U.S.
“The company said it would extend the limits introduced for Wegovy supplies, having said in May that it would halve supply of starter doses to the U.S. market for several months to ensure supplies for existing patients.” CEO Lars Fruergaard Jorgensen told journalists,"We've seen that the initiative we took earlier this year, limiting the starter dose, has actually helped manage those dynamics. So we want to extend that in the coming quarters."
The World Health Organization estimates more than 650 million adults are obese and another 1.3 billion are overweight. Obesity contributes to many health issues, including heart disease and diabetes.© 2023 WebMD, LLC. All rights reserved.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Read more »
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Read more »
Wegovy-maker Novo Nordisk extends curb on supply of weight-loss drug, raises outlookThe Danish drugmaker confirmed that it will continue to restrict the lower-dose strengths of Wegovy as it strives to keep up with demand.
Read more »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »